Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Hepatocellular
/ pathology
Female
Hepatitis B
/ complications
Hepatitis B virus
Hepatitis B, Chronic
/ complications
Humans
Liver Neoplasms
/ pathology
Male
Middle Aged
Republic of Korea
/ epidemiology
Retrospective Studies
Virus Diseases
/ complications
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
11
2021
accepted:
02
03
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
6
5
2022
Statut:
epublish
Résumé
The incidence and mortality of hepatocellular carcinoma (HCC) have decreased over time in South Korea, where hepatitis B virus (HBV) in endemic. This study investigated the changes in the characteristics and clinical outcomes of HCC patients in Korea. Patients initially diagnosed with HCC and treated at the National Cancer Center, Korea between 2000 and 2015 (n = 4,291) were followed up until February 2017. Differences in patient characteristics and outcomes were compared between chronological cohorts: cohort A (2000-2004, n = 1,157) vs. B (2005-2009, n = 1,678) vs. C (2010-2015, n = 1,456). The median age of the patient cohort was 57 years (range, 13-98 years), and male predominance was noted (81.6%). HBV infection was the most common etiology (74.8%). The proportion of patients diagnosed with good liver function and small tumors (<2 cm) increased significantly over time: 74.6%, 79.9%, and 87.4% for Child-Pugh class A (p<0.001) and 8.0%, 8.5%, and 12.0% for modified UICC stage I (p<0.001) in cohorts A, B, and C, respectively. Median overall survival improved significantly over time: 14.4 months (95% confidence interval [CI], 12.0-16.8 months), 22.9 months (95% CI, 20.3-25.5 months), and 53.6 months (95% CI, 45.7-61.5 months) in cohorts A, B, and C, respectively. HBV-related patients showed significantly improved survival (12.7 vs. 20.4 vs. 64.5 months, p<0.001) associated with the use of antiviral treatments (adjusted hazard ratio, 0.72; 95% CI, 0.64-0.80). The survival of patients with HCC, especially HBV-related HCC, has improved significantly over time in Korea.
Identifiants
pubmed: 35324973
doi: 10.1371/journal.pone.0265668
pii: PONE-D-21-37665
pmc: PMC8947113
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265668Déclaration de conflit d'intérêts
The authors declare that they do not have anything to disclose or conflict of interest with respect to this manuscript.
Références
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Hepatology. 2015 Apr;61(4):1154-62
pubmed: 25476749
Korean J Hepatol. 2009 Sep;15(3):391-423
pubmed: 19783891
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
N Engl J Med. 2006 Mar 9;354(10):1011-20
pubmed: 16525138
J Hepatol. 2020 Nov;73(5):1037-1045
pubmed: 32553667
J Gastroenterol Hepatol. 2020 Oct;35(10):1774-1781
pubmed: 32154938
JAMA. 2013 Sep 4;310(9):974-6
pubmed: 24002285
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22
pubmed: 15042359
Gut Liver. 2015 May 23;9(3):267-317
pubmed: 25918260
Hepatol Res. 2002 Dec;24(4):395-403
pubmed: 12479938
Gut Liver. 2019 May 15;13(3):227-299
pubmed: 31060120
Gut Liver. 2016 Nov 15;10(6):939-947
pubmed: 27282264
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
J Gastroenterol Hepatol. 2008 Mar;23(3):467-73
pubmed: 17764529
Aliment Pharmacol Ther. 2011 May;33(10):1104-12
pubmed: 21488914
N Engl J Med. 2006 Mar 9;354(10):1001-10
pubmed: 16525137
Gut. 2020 Jul;69(7):1301-1308
pubmed: 31672838
Hepatology. 2021 Jun;73(6):2155-2166
pubmed: 33131063
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Asian Pac J Cancer Prev. 2013;14(11):6459-63
pubmed: 24377550
J Gastroenterol Hepatol. 2014 Apr;29(4):820-9
pubmed: 24325272
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Clin Mol Hepatol. 2019 Sep;25(3):264-269
pubmed: 30827081
Cancer Res Treat. 2012 Jun;44(2):113-20
pubmed: 22802749
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Clin Mol Hepatol. 2021 Jul;27(3):402-412
pubmed: 34157830
Clin Mol Hepatol. 2017 Sep;23(3):189-195
pubmed: 28942620
Clin Gastroenterol Hepatol. 2007 Aug;5(8):921-31
pubmed: 17678844
Clin Mol Hepatol. 2021 Jul;27(3):512-514
pubmed: 34153973
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
pubmed: 15508102
Nat Rev Clin Oncol. 2009 Sep;6(9):505-6
pubmed: 19707242
Cancer Res Treat. 2017 Apr;49(2):292-305
pubmed: 28279062
Clin Mol Hepatol. 2018 Mar;24(1):1-9
pubmed: 29249129